Why siRNA Process Development Is Technically Demanding
siRNA therapeutics sit at the intersection of synthetic chemistry, molecular biology, analytical science and drug delivery. A successful program must connect sequence design, chemical modification, solid-phase synthesis, purification, delivery strategy, quality control and scale-up. Weakness in any one part can delay the whole program.
Unlike many small molecules, siRNA products are large, charged and sequence-defined. They contain many chemically similar repeating units. Their impurities may differ from the target by one nucleotide, one modification, one sulfur atom or one small degradation event. This makes analysis and purification difficult. At the same time, siRNA molecules must be stable enough for biological use but still compatible with RNAi machinery inside the cell.
The process-development challenge is therefore not only "make the sequence." It is to make the right sequence, with the right modification pattern, at the right purity, in a form that can be delivered, analyzed and scaled.
Sequence Design and Chemical Modification
Sequence design affects potency, specificity and safety. Developers usually evaluate target accessibility, GC content, thermodynamic asymmetry, seed-region behavior, off-target potential and immune-stimulatory motifs. Candidate sequences may perform differently even when they target the same gene.
Chemical modifications are used to improve stability and reduce immune recognition. Common modifications include 2'-O-methyl, 2'-fluoro, phosphorothioate linkages and other sugar or backbone modifications. These modifications can improve nuclease resistance and pharmacokinetics, but they must be placed carefully. Over-modification can reduce RISC loading or target cleavage.
From a manufacturing perspective, each modification adds complexity. Modified phosphoramidites may be expensive, moisture-sensitive or less reactive. Phosphorothioate linkages introduce stereochemical complexity. Terminal ligands such as GalNAc or other conjugates may reduce coupling efficiency or complicate purification.
The relationship between design and process is easy to underestimate. A sequence selected only for potency may later prove difficult to synthesize or purify. A modification pattern chosen for stability may create weak coupling positions or difficult impurity clusters. A terminal conjugate may improve delivery but reduce overall yield. For this reason, CMC thinking should begin before the final lead is locked.
| Design choice | Process-development implication |
|---|---|
| High GC content | May affect duplex behavior and analytical method development |
| Multiple 2'-modified nucleotides | Can change monomer reactivity and coupling time requirements |
| Several PS linkages | Adds phosphorus stereochemical complexity and analytical burden |
| Terminal GalNAc conjugation | Requires bulky building block or post-synthetic conjugation strategy |
| Longer duplex design | Increases cumulative synthesis loss and purification challenge |
| Unusual linker or spacer | May require custom building-block synthesis and impurity mapping |
Solid-Phase Phosphoramidite Synthesis
Most oligonucleotide manufacturing relies on solid-phase phosphoramidite chemistry. The sequence is built from the 3' end to the 5' end through repeated cycles of detritylation, coupling, oxidation or sulfurization, and capping. After chain assembly, cleavage and deprotection release the oligonucleotide from the solid support and remove protecting groups.
The key limitation is cumulative yield. Even a high per-step coupling efficiency can lead to meaningful loss over a long sequence. If a 21-mer requires many coupling steps, small inefficiencies create N-1, N-2 and other truncated species. Modified monomers may couple less efficiently than standard monomers, increasing the challenge.
Process parameters such as reagent water content, activator choice, coupling time, acid exposure, sulfurization efficiency and wash conditions all matter. For RNA and heavily modified sequences, deprotection conditions must be selected carefully to avoid degradation while fully removing protecting groups.
Purification and Annealing Challenges
Crude oligonucleotide mixtures contain full-length product, truncated sequences, extended sequences, depurinated products, deaminated products, capping byproducts, phosphorothioate-related species and residual small molecules. These impurities can be structurally similar to the target, making separation difficult.
Ion-exchange chromatography and reverse-phase HPLC are common purification tools. Ion exchange separates mainly by charge and length, while reverse-phase methods rely more on hydrophobicity and ion-pair interactions. Tangential flow filtration may be used for desalting, buffer exchange and concentration.
For double-stranded siRNA, two single strands must be produced, purified and annealed. Annealing introduces additional quality questions: correct duplex formation, residual single strands, mismatched duplexes and aggregates. Analytical methods must examine both single-strand purity and duplex integrity.
Delivery System Development
siRNA delivery is a process-development topic, not only a pharmacology topic. LNP formulations require high-quality lipids, controlled mixing and particle characterization. GalNAc conjugates require robust ligand-linker chemistry and chemically stabilized RNA. Other delivery strategies introduce their own material and analytical needs.
Delivery-system choice can affect synthesis and quality control. A GalNAc program may require specialized building blocks and conjugation methods. An LNP program may require ionizable lipids, PEG-lipids, sterols and formulation-sensitive documentation. Early alignment between delivery design and material supply can prevent later bottlenecks.
For example, an LNP program may begin by screening several ionizable lipid analogs. If those analogs are sourced with inconsistent purity, oxidation status or salt form, the formulation team may spend weeks interpreting noisy results. A GalNAc program may depend on a triantennary ligand building block. If that building block is difficult to reproduce or contains partially substituted impurities, the conjugation process may become unstable. In both cases, upstream chemistry directly affects downstream biological and formulation decisions.
Analytical Control and Critical Quality Attributes
siRNA development requires orthogonal analytical methods. No single technique captures the full picture. HPLC can evaluate purity. LC-MS can confirm mass and identify impurities. UV can support concentration measurement. Capillary electrophoresis can provide complementary separation. NMR, ion chromatography, Karl Fischer titration and residual solvent methods may also be relevant.
Critical quality attributes may include identity, purity, sequence confirmation, water content, counterion profile, residual solvents, endotoxin, duplex formation, ligand conjugation completeness and formulation-specific attributes such as particle size or encapsulation efficiency.
A practical control strategy should reflect development stage. Early discovery needs speed and flexibility. Later-stage development needs stronger specifications, method qualification, impurity understanding and batch comparability.
An effective analytical plan should answer three questions. First, is the intended molecule present? Second, what related impurities are present and where did they come from? Third, will the method detect changes that matter during storage, scale-up or formulation? If the answer to the third question is unclear, the method may be useful for identity confirmation but weak as a development tool.
For CHEMOS customers working with custom intermediates rather than finished oligonucleotide drug substances, the same logic still applies. A linker, lipid or GalNAc building block should be characterized well enough that downstream teams can trust the material. This may include NMR, LC-MS, HPLC, residual solvents, water content or special stability checks, depending on structure.
Scale-Up and Batch Consistency
Scaling siRNA-related processes is not linear. In solid-phase synthesis, larger columns can introduce mass-transfer limitations, uneven reagent distribution and pressure effects. Reagent consumption increases significantly. Purification scale-up may reduce resolution if column loading, gradient slope or resin selection are not optimized.
For LNP formulation, scale-up must preserve mixing time and particle formation behavior. For GalNAc conjugates, scale-up must preserve coupling efficiency and impurity control. In both cases, batch consistency depends on understanding critical process parameters and critical material attributes.
How CHEMOS Supports Nucleic Acid-Related Material Development
CHEMOS can support custom synthesis, route development, process optimization and analytical support for delivery-related materials, LNP lipids, GalNAc building blocks, linkers, PEG spacers and specialty intermediates. CHEMOS can help customers evaluate target structures, batch size, specification needs, impurity risks and scale-up feasibility.
For siRNA-related programs, the right material partner can reduce technical uncertainty. High-quality intermediates and delivery-related building blocks make downstream synthesis, formulation and analytical work more predictable.
FAQ
What is the hardest part of siRNA process development?
The hardest part is often the combination of synthesis, impurity control, purification and delivery. These areas are closely connected.
Why are oligonucleotide impurities difficult to control?
Many impurities are structurally similar to the target sequence and may differ by only one nucleotide or one small chemical change.
How can CHEMOS participate in siRNA-related development programs?
CHEMOS supports siRNA-related programs through custom synthesis of intermediates, delivery-related materials, LNP lipids, GalNAc building blocks, linkers and analytical support. This positions CHEMOS as a chemistry and material-development partner rather than a finished siRNA drug-product manufacturer.
References and Further Reading
- Setten RL, Rossi JJ, Han SP. The current state and future directions of RNAi-based therapeutics. Nature Reviews Drug Discovery, 2019. https://doi.org/10.1038/s41573-019-0017-4
- Roberts TC, Langer R, Wood MJA. Advances in oligonucleotide drug delivery. Nature Reviews Drug Discovery, 2020. https://doi.org/10.1038/s41573-020-0075-7
- Kulkarni JA, Witzigmann D, Chen S, Cullis PR, van der Meel R. The current landscape of nucleic acid therapeutics. Nature Nanotechnology, 2021. https://doi.org/10.1038/s41565-021-00898-0
- Crooke ST, Baker BF, Crooke RM, Liang XH. Antisense technology: an overview and prospectus. Nature Reviews Drug Discovery, 2021. https://doi.org/10.1038/s41573-021-00162-z
- ICH Q11. Development and Manufacture of Drug Substances. https://www.ich.org/page/quality-guidelines